Infertility drugs market size was valued at USD 3.98 billion in 2024 and is expected to reach USD 6.36 billion by 2032, growing at a CAGR of 6.03% over the forecast period 2025-2032.
Rising infertility rates, changing reproductive health consciousness, and strong government support are driving dynamic expansion in the infertility drugs market.
For example, the World Health Organization (WHO) estimates that 48 million couples and 186 million people globally suffer from infertility; the Centers for Disease Control and Prevention (CDC) notes that 12% of American women between the ages of 15 and 44 suffer from infertility as well. Delayed childbirth, environmental exposures, and lifestyle changes are all contributing to declining fertility rates.
The growing incidence of infertility, technological advancements in fertility hormone treatments, and good government policies define the main forces behind the infertility drugs market. Recent data from the WHO and the CDC highlight a global increase in infertility, for which millions of people are looking for effective drugs for infertility. Treatment outcomes and market adoption have been enhanced by the explosion of fertility clinics and integration of modern assisted reproductive technologies (ART), particularly in-vitro fertilization (IVF), supported by a robust network of 489 fertility clinics and modern ART centers.
The U.S. infertility drugs market size valued at USD 1.21 billion in 2024, is predicted to reach USD 1.92 billion by 2032 with a CAGR of 5.92%. With rising research and development (R&D) investment, these elements are driving demand for infertility treatment drugs and shaping the most current Infertility drugs market trends.
Prescription infertility drugs are becoming more easily available thanks to government programs, including increased insurance coverage for ART and fertility medications, therefore boosting the expansion of the infertility drugs market.
For instance, the Ministry of Health, Labour and Welfare of Japan adopted a policy in April 2022, paying 70% of fertility treatment costs, while the National Health Service (NHS) of the UK keeps granting access to essential fertility drugs, as governments are reacting actively.
Drivers
Recent Drug Innovations and Updated Safety Policies Transform the Infertility Drugs Market
With regulatory bodies seeking strong clinical proof for novel treatments, recent advancements in the infertility drugs industry have concentrated on enhancing treatment efficacy and patient safety.
For instance, Ferring Pharmaceuticals reported favorable findings from the BEYOND study on April 29, 2024, proving the safety and efficacy of follitropin delta (Rekovelle®) in women undergoing IVF under a GnRH agonist schedule.
Compared to traditional gonadotropins, clinical studies show that Ferostim greatly reduces the risk of ovarian hyperstimulation syndrome main in-vitro fertilization (IVF) complication. Reflecting the strict criteria established by authorities such as the FDA and EMA, regulatory approval for Ferostim demanded thorough safety and efficacy evidence, including pharmacodynamic and toxicological profiles. Aiming to maximize endometrial receptivity and ovarian stimulation, Merck & Company advanced a unique combination therapy coupling an oral hormone medication with a new injection in tandem, hence increasing in-vitro fertilization (IVF) success rates. This development fits a larger trend of strategic alliances and mergers in the reproductive medication industry, which lets businesses speed R&D and more effectively negotiate difficult regulatory paths.
On the safety front, the American Society for Reproductive Medicine (ASRM) updated its 2024 guidelines, underlining that, although fertility drugs are not definitively linked to increased risks for most cancers, especially with prolonged or high-dose use of clomiphene, there may be a small raised risk for ovarian and endometrial cancers. These recommendations advise women to be completely educated about possible hazards and to approach protracted treatment cycles carefully, therefore guaranteeing patient safety as the market evolves.
Restrain
Insurance Coverage Gaps and Excessive Costs Limit Access to Infertility Treatments
For many individuals, the high cost of infertility treatments and limited insurance coverage remain primary obstacles & major barriers for many patients.
For instance, the Department of Health and Human Services (2024) states that the average patient needs 2.5 cycles to get pregnant; a single round of IVF may cost USD 15,000 to USD 30,000.
As of 2024, only 19 U.S. mandate insurance coverage for infertility treatments 2024, leaving the majority of patients to pay out-of-pocket or forgo care altogether. Those in lower-income groups and areas without mandated coverage bear more of this financial load, which causes notable differences in treatment access. The National Infertility Association notes that the geographic concentration of fertility clinics in wealthy areas further complicates the absence of thorough insurance support. These structural problems draw attention to the need for legislative changes and more general insurance requirements to provide fair access to infertility treatment drugs. Dealing with these cost and coverage gaps will be crucial as clinical trial activity and drug innovation speed forward to translate scientific discoveries into practical advantages for every individual and couple dealing with infertility.
By drug class
With a 39% revenue share in 2024, the gonadotropins segment leads the infertility drugs market and is expected to see the highest growth. Especially in ART and IVF cycles, gonadotropins, including recombinant FSH and hCG, are indispensable fertility treatments for ovulation induction drugs and hormonal therapy for infertility. Addressing a wide range of reproductive difficulties, their clinical efficacy makes them the recommended choice for both male and female infertility medications.
Agency regulatory approvals from bodies such as the FDA and EMA guarantee the effectiveness and safety of these new infertility treatment drugs. Furthermore, broadening the range of in-vitro fertilization (IVF) medications and male infertility pharmaceuticals, China's fertility clinics are pioneering stem cell-based fertility hormone therapy for male infertility. With AI-driven reproductive prediction tools and recombinant hormone treatments customizing treatment protocols for improved outcomes, the infertility drugs market analysis highlights a trend toward personalized medicine.
By Distribution channels
In 2024, the hospital pharmacies segment dominated the infertility drugs market with a 53% revenue share because of centralized access, patient safety, and connection with ART centers and fertility clinics. Under strict medical supervision, hospital pharmacies are vital for administering complicated hormonal therapy, including gonadotropins and ovulation induction medicines, under close medical control.
However, the online pharmacy segment is rapidly emerging as a key growth driver, anticipated to rise at a noteworthy CAGR of 6.63%. Particularly for patients in remote areas or those looking for discretion with reproductive drugs, online pharmacies provide convenience, privacy, and access. The emergence of digital health platforms and telemedicine, which cooperate with fertility clinics, is simplifying access to prescription infertility drugs and thereby boosting the most recent infertility drugs market trends. The significance of these distribution channels in the worldwide infertility medications industry is underlined by the CDC's documentation on ART operations and the spread of hospital-based fertility clinics.
By end user
With a 73% market share in 2024, the women segment leads the infertility drugs market and is projected to witness the fastest growth.
For instance, according to the U.S. Department of Health and Human Services, in the United States, infertility affects around 11% of women and 9% of males of reproductive age.
With 12% of U.S. women between the ages of 15 and 44 afflicted, female infertility is a major contributor and generates great demand for ovulation induction pharmaceuticals and female infertility drugs. Following fertility guidance (78%) and fertility testing (61%), which makes fertility medications are among the most often utilized therapies. To treat disorders including polycystic ovary syndrome (PCOS) and endometriosis, women sometimes need more sophisticated hormonal therapy involving fertility hormone therapies and IVF medicines. The increasing adoption of assisted reproductive technology (ART) and IVF among women is driving demand for prescription infertility medications tailored to female needs.
North America dominated the infertility drugs market in 2024, with a 39% share; the U.S. infertility drugs market accounted for 78% of the NA region's share. Advanced healthcare infrastructure, a great concentration of fertility clinics (489 ART centers in the United States), and thorough government laws extending insurance coverage for assisted reproductive technology (ART) and fertility hormone treatments help to explain this dominance. The CDC's estimates of ART use and infertility frequency underline even more the region's leadership in reproductive health.
The Asia-Pacific is the fastest-growing region with a projected CAGR of 6.53% during 2025-2032. Rising infertility rates, growing medical tourism, and government backing are driving the rapid infertility drugs market growth. Access to modern reproductive care has been much enhanced by Japan's choice to cover 70% of fertility treatment expenses and India's role as a main provider of reasonably priced generic infertility treatment drugs.
Europe held a significant infertility drugs market share, with strong demand in Germany, France, and the UK among other nations. Government programs improving access and affordability include Germany's support of biosimilar infertility treatment pharmaceuticals and the coverage of fertility meds by the NHS. Strict EU rules are driving the development of safer, alternative female infertility drugs as well as boosting the overall IVF drugs market.
The LAMEA region is experiencing moderate growth, driven by the expansion of assisted reproductive technology (ART) facilities and rising government support for reproductive health. Although access is still a problem in some places, increasing awareness and investment could help the region’s participation in the global infertility drugs market.
The key Infertility Drugs companies are Teva Pharmaceutical Industries Ltd., Merck & Co., Inc., Ferring B.V., Abbott, Novartis AG, Bayer AG, Livzon, Mankind Pharma, Sanofi, Pfizer Inc., IBSA Institut Biochimique SA, and others.
Advances in genomic screening in 2024 have improved implantation success rates by increasing the accuracy of preimplantation genetic testing (PGT), therefore allowing more reliable diagnosis of genetic issues in embryos.
Lupin introduced in February 2024 a prefilled, single-dose syringe called Ganirelix Acetate Injection to stop early LH surges in women undergoing ovarian stimulation.
| Report Attributes | Details |
|---|---|
| Market Size in 2024 | USD 3.98 Billion |
| Market Size by 2032 | USD 6.36 Billion |
| CAGR | CAGR of 6.03% From 2025 to 2032 |
| Base Year | 2024 |
| Forecast Period | 2025-2032 |
| Historical Data | 2021-2023 |
| Report Scope & Coverage | Market Size, Segments Analysis, Competitive Landscape, Regional Analysis, DROC & SWOT Analysis, Forecast Outlook |
| Key Segments | • By Drug Class (Gonadotropins, Dopamine Agonists, Aromatase Inhibitors, Selective Estrogen Receptor Modulators (SERMs), and Others) • By Distribution Channel (Hospital Pharmacy, Online Pharmacy, and Specialty & Retail Pharmacy) • By End-user (Women, and Men) |
| Regional Analysis/Coverage | North America (US, Canada, Mexico), Europe (Germany, France, UK, Italy, Spain, Poland, Turkey, Rest of Europe), Asia Pacific (China, India, Japan, South Korea, Singapore, Australia, Rest of Asia Pacific), Middle East & Africa (UAE, Saudi Arabia, Qatar, South Africa, Rest of Middle East & Africa), Latin America (Brazil, Argentina, Rest of Latin America) |
| Company Profiles | Teva Pharmaceutical Industries Ltd., Merck & Co., Inc., Ferring B.V., Abbott, Novartis AG, Bayer AG, Livzon, Mankind Pharma, Sanofi, Pfizer Inc., IBSA Institut Biochimique SA |
Ans. The projected market size for the Infertility Drugs Market is USD 6.36 billion by 2032.
Ans: The North American region dominated the Infertility Drugs Market in 2023.
Ans. The CAGR of the Infertility Drugs Market is 6.03% during the forecast period of 2025-2032.
Ans: Recent drug innovations and updated safety policies transform the infertility drugs market.
Ans: The Hospital Pharmacies segment dominated the Infertility Drugs Market.
1. Introduction
1.1 Market Definition
1.2 Scope (Inclusion and Exclusions)
1.3 Research Assumptions
2. Executive Summary
2.1 Market Overview
2.2 Regional Synopsis
2.3 Competitive Summary
3. Research Methodology
3.1 Top-Down Approach
3.2 Bottom-up Approach
3.3. Data Validation
3.4 Primary Interviews
4. Market Dynamics Impact Analysis
4.1 Market Driving Factors Analysis
4.1.1 Drivers
4.1.2 Restraints
4.1.3 Opportunities
4.1.4 Challenges
4.2 PESTLE Analysis
4.3 Porter’s Five Forces Model
5. Statistical Insights and Trends Reporting
5.1 Incidence and Prevalence of Infertility (2024)
5.2 Drug Volume Trends – Production vs. Consumption (2020–2024)
5.3 Healthcare Spending Allocation for Infertility Treatments (2024)
5.4 Treatment Success Rates and Time-to-Conception Statistics (2024)
6. Competitive Landscape
6.1 List of Major Companies, By Region
6.2 Market Share Analysis, By Region
6.3 Product Benchmarking
6.3.1 Product specifications and features
6.3.2 Pricing
6.4 Strategic Initiatives
6.4.1 Marketing and promotional activities
6.4.2 Distribution and Supply Chain Strategies
6.4.3 Expansion plans and new Product launches
6.4.4 Strategic partnerships and collaborations
6.5 Technological Advancements
6.6 Market Positioning and Branding
7. Infertility Drugs Market Segmentation By Drug Class
7.1 Chapter Overview
7.2 Gonadotropins
7.2.1 Gonadotropins Market Trends Analysis (2021-2032)
7.2.2 Gonadotropins Market Size Estimates and Forecasts to 2032 (USD Billion)
7.3 Dopamine Agonists
7.3.1 Dopamine Agonists Market Trends Analysis (2021-2032)
7.3.2 Dopamine Agonists Market Size Estimates and Forecasts to 2032 (USD Billion)
7.4 Aromatase Inhibitors
7.4.1 Aromatase Inhibitors Market Trends Analysis (2021-2032)
7.4.2 Aromatase Inhibitors Market Size Estimates and Forecasts to 2032 (USD Billion)
7.5 Selective Estrogen Receptor Modulators (SERMs)
7.5.1 Selective Estrogen Receptor Modulators (SERMs) Market Trends Analysis (2021-2032)
7.5.2 Selective Estrogen Receptor Modulators (SERMs) Market Size Estimates and Forecasts to 2032 (USD Billion)
7.6 Others
7.6.1 Others Market Trends Analysis (2021-2032)
7.6.2 Others Market Size Estimates and Forecasts to 2032 (USD Billion)
8. Infertility Drugs Market Segmentation By Distribution Channel
8.1 Chapter Overview
8.2 Hospital Pharmacy
8.2.1 Hospital Pharmacy Market Trend Analysis (2021-2032)
8.2.2 Hospital Pharmacy Market Size Estimates and Forecasts to 2032 (USD Billion)
8.3 Online Pharmacy
8.3.1 Online Pharmacy Market Trends Analysis (2021-2032)
8.3.2 Online Pharmacy Market Size Estimates and Forecasts to 2032 (USD Billion)
8.4 Specialty & Retail Pharmacy
8.4.1 Specialty & Retail Pharmacy Market Trends Analysis (2021-2032)
8.4.2 Specialty & Retail Pharmacy Market Size Estimates and Forecasts to 2032 (USD Billion)
9. Infertility Drugs Market Segmentation By End-user
9.1 Chapter Overview
9.2 Women
9.2.1 Women Market Trends Analysis (2021-2032)
9.2.2 Women Market Size Estimates and Forecasts to 2032 (USD Billion)
9.3 Men
9.3.1 Men Market Trends Analysis (2021-2032)
9.3.2 Men Market Size Estimates and Forecasts to 2032 (USD Billion)
10. Regional Analysis
10.1 Chapter Overview
10.2 North America
10.2.1 Trends Analysis
10.2.2 North America Infertility Drugs Market Estimates and Forecasts, by Country (2021-2032) (USD Billion)
10.2.3 North America Infertility Drugs Market Estimates and Forecasts, By Drug Class (2021-2032) (USD Billion)
10.2.4 North America Infertility Drugs Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
10.2.5 North America Infertility Drugs Market Estimates and Forecasts, By End-user (2021-2032) (USD Billion)
10.2.6 USA
10.2.6.1 USA Infertility Drugs Market Estimates and Forecasts, By Drug Class (2021-2032) (USD Billion)
10.2.6.2 USA Infertility Drugs Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
10.2.6.3 USA Infertility Drugs Market Estimates and Forecasts, By End-user (2021-2032) (USD Billion)
10.2.7 Canada
10.2.7.1 Canada Infertility Drugs Market Estimates and Forecasts, By Drug Class (2021-2032) (USD Billion)
10.2.7.2 Canada Infertility Drugs Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
10.2.7.3 Canada Infertility Drugs Market Estimates and Forecasts, By End-user (2021-2032) (USD Billion)
10.2.8 Mexico
10.2.8.1 Mexico Infertility Drugs Market Estimates and Forecasts, By Drug Class (2021-2032) (USD Billion)
10.2.8.2 Mexico Infertility Drugs Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
10.2.8.3 Mexico Infertility Drugs Market Estimates and Forecasts, By End-user (2021-2032) (USD Billion)
10.3 Europe
10.3.1 Trends Analysis
10.3.2 Europe Infertility Drugs Market Estimates and Forecasts, by Country (2021-2032) (USD Billion)
10.3.3 Europe Infertility Drugs Market Estimates and Forecasts, By Drug Class (2021-2032) (USD Billion)
10.3.4 Europe Infertility Drugs Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
10.3.5 Europe Infertility Drugs Market Estimates and Forecasts, By End-user (2021-2032) (USD Billion)
10.3.6 Germany
10.3.6.1 Germany Infertility Drugs Market Estimates and Forecasts, By Drug Class (2021-2032) (USD Billion)
10.3.6.2 Germany Infertility Drugs Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
10.3.6.3 Germany Infertility Drugs Market Estimates and Forecasts, By End-user (2021-2032) (USD Billion)
10.3.7 France
10.3.7.1 France Infertility Drugs Market Estimates and Forecasts, By Drug Class (2021-2032) (USD Billion)
10.3.7.2 France Infertility Drugs Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
10.3.7.3 France Infertility Drugs Market Estimates and Forecasts, By End-user (2021-2032) (USD Billion)
10.3.8 UK
10.3.8.1 UK Infertility Drugs Market Estimates and Forecasts, By Drug Class (2021-2032) (USD Billion)
10.3.8.2 UK Infertility Drugs Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
10.3.8.3 UK Infertility Drugs Market Estimates and Forecasts, By End-user (2021-2032) (USD Billion)
10.3.9 Italy
10.3.9.1 Italy Infertility Drugs Market Estimates and Forecasts, By Drug Class (2021-2032) (USD Billion)
10.3.9.2 Italy Infertility Drugs Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
10.3.9.3 Italy Infertility Drugs Market Estimates and Forecasts, By End-user (2021-2032) (USD Billion)
10.3.10 Spain
10.3.10.1 Spain Infertility Drugs Market Estimates and Forecasts, By Drug Class (2021-2032) (USD Billion)
10.3.10.2 Spain Infertility Drugs Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
10.3.10.3 Spain Infertility Drugs Market Estimates and Forecasts, By End-user (2021-2032) (USD Billion)
10.3.11 Poland
10.3.11.1 Poland Infertility Drugs Market Estimates and Forecasts, By Drug Class (2021-2032) (USD Billion)
10.3.11.2 Poland Infertility Drugs Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
10.3.11.3 Poland Infertility Drugs Market Estimates and Forecasts, By End-user (2021-2032) (USD Billion)
10.3.12 Turkey
10.3.12.1 Turkey Infertility Drugs Market Estimates and Forecasts, By Drug Class (2021-2032) (USD Billion)
10.3.12.2 Turkey Infertility Drugs Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
10.3.12.3 Turkey Infertility Drugs Market Estimates and Forecasts, By End-user (2021-2032) (USD Billion)
10.3.13 Rest of Europe
10.3.13.1 Rest of Europe Infertility Drugs Market Estimates and Forecasts, By Drug Class (2021-2032) (USD Billion)
10.3.13.2 Rest of Europe Infertility Drugs Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
10.3.13.3 Rest of Europe Infertility Drugs Market Estimates and Forecasts, By End-user (2021-2032) (USD Billion)
10.4 Asia Pacific
10.4.1 Trends Analysis
10.4.2 Asia Pacific Infertility Drugs Market Estimates and Forecasts, by Country (2021-2032) (USD Billion)
10.4.3 Asia Pacific Infertility Drugs Market Estimates and Forecasts, By Drug Class (2021-2032) (USD Billion)
10.4.4 Asia Pacific Infertility Drugs Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
10.4.5 Asia Pacific Infertility Drugs Market Estimates and Forecasts, By End-user (2021-2032) (USD Billion)
10.4.6 China
10.4.6.1 China Infertility Drugs Market Estimates and Forecasts, By Drug Class (2021-2032) (USD Billion)
10.4.6.2 China Infertility Drugs Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
10.4.6.3 China Infertility Drugs Market Estimates and Forecasts, By End-user (2021-2032) (USD Billion)
10.4.7 India
10.4.7.1 India Infertility Drugs Market Estimates and Forecasts, By Drug Class (2021-2032) (USD Billion)
10.4.7.2 India Infertility Drugs Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
10.4.7.3 India Infertility Drugs Market Estimates and Forecasts, By End-user (2021-2032) (USD Billion)
10.4.8 Japan
10.4.8.1 Japan Infertility Drugs Market Estimates and Forecasts, By Drug Class (2021-2032) (USD Billion)
10.4.8.2 Japan Infertility Drugs Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
10.4.8.3 Japan Infertility Drugs Market Estimates and Forecasts, By End-user (2021-2032) (USD Billion)
10.4.9 South Korea
10.4.9.1 South Korea Infertility Drugs Market Estimates and Forecasts, By Drug Class (2021-2032) (USD Billion)
10.4.9.2 South Korea Infertility Drugs Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
10.4.9.3 South Korea Infertility Drugs Market Estimates and Forecasts, By End-user (2021-2032) (USD Billion)
10.4.10 Singapore
10.4.10.1 Singapore Infertility Drugs Market Estimates and Forecasts, By Drug Class (2021-2032) (USD Billion)
10.4.10.2 Singapore Infertility Drugs Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
10.4.10.3 Singapore Infertility Drugs Market Estimates and Forecasts, By End-user (2021-2032) (USD Billion)
10.4.11 Australia
10.4.11.1 Australia Infertility Drugs Market Estimates and Forecasts, By Drug Class (2021-2032) (USD Billion)
10.4.11.2 Australia Infertility Drugs Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
10.4.11.3 Australia Infertility Drugs Market Estimates and Forecasts, By End-user (2021-2032) (USD Billion)
10.4.12 Rest of Asia Pacific
10.4.12.1 Rest of Asia Pacific Infertility Drugs Market Estimates and Forecasts, By Drug Class (2021-2032) (USD Billion)
10.4.12.2 Rest of Asia Pacific Infertility Drugs Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
10.4.12.3 Rest of Asia Pacific Infertility Drugs Market Estimates and Forecasts, By End-user (2021-2032) (USD Billion)
10.5 Middle East and Africa
10.5.1 Trends Analysis
10.5.2 Middle East and Africa Infertility Drugs Market Estimates and Forecasts, by Country (2021-2032) (USD Billion)
10.5.3 Middle East and Africa Infertility Drugs Market Estimates and Forecasts, By Drug Class (2021-2032) (USD Billion)
10.5.4 Middle East and Africa Infertility Drugs Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
10.5.5 Middle East and Africa Infertility Drugs Market Estimates and Forecasts, By End-user (2021-2032) (USD Billion)
10.5.6 UAE
10.5.6.1 UAE Infertility Drugs Market Estimates and Forecasts, By Drug Class (2021-2032) (USD Billion)
10.5.6.2 UAE Infertility Drugs Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
10.5.6.3 UAE Infertility Drugs Market Estimates and Forecasts, By End-user (2021-2032) (USD Billion)
10.5.7 Saudi Arabia
10.5.7.1 Saudi Arabia Infertility Drugs Market Estimates and Forecasts, By Drug Class (2021-2032) (USD Billion)
10.5.7.2 Saudi Arabia Infertility Drugs Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
10.5.7.3 Saudi Arabia Infertility Drugs Market Estimates and Forecasts, By End-user (2021-2032) (USD Billion)
10.5.8 Qatar
10.5.8.1 Qatar Infertility Drugs Market Estimates and Forecasts, By Drug Class (2021-2032) (USD Billion)
10.5.8.2 Qatar Infertility Drugs Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
10.5.8.3 Qatar Infertility Drugs Market Estimates and Forecasts, By End-user (2021-2032) (USD Billion)
10.5.9 South Africa
10.5.9.1 South Africa Infertility Drugs Market Estimates and Forecasts, By Drug Class (2021-2032) (USD Billion)
10.5.9.2 South Africa Infertility Drugs Market Estimates and Forecasts By Distribution Channel (2021-2032) (USD Billion)
10.5.9.3 South Africa Infertility Drugs Market Estimates and Forecasts, By End-user (2021-2032) (USD Billion)
10.5.10 Rest of Middle East & Africa
10.5.10.1 Rest of Middle East & Africa Infertility Drugs Market Estimates and Forecasts, By Drug Class (2021-2032) (USD Billion)
10.5.10.2 Rest of Middle East & Africa Infertility Drugs Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
10.5.10.3 Rest of Middle East & Africa Infertility Drugs Market Estimates and Forecasts, By End-user (2021-2032) (USD Billion)
10.6 Latin America
10.6.1 Trends Analysis
10.6.2 Latin America Infertility Drugs Market Estimates and Forecasts, by Country (2021-2032) (USD Billion)
10.6.3 Latin America Infertility Drugs Market Estimates and Forecasts, By Drug Class (2021-2032) (USD Billion)
10.6.4 Latin America Infertility Drugs Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
10.6.5 Latin America Infertility Drugs Market Estimates and Forecasts, By End-user (2021-2032) (USD Billion)
10.6.6 Brazil
10.6.6.1 Brazil Infertility Drugs Market Estimates and Forecasts, By Drug Class (2021-2032) (USD Billion)
10.6.6.2 Brazil Infertility Drugs Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
10.6.6.3 Brazil Infertility Drugs Market Estimates and Forecasts, By End-user (2021-2032) (USD Billion)
10.6.7 Argentina
10.6.7.1 Argentina Infertility Drugs Market Estimates and Forecasts, By Drug Class (2021-2032) (USD Billion)
10.6.7.2 Argentina Infertility Drugs Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
10.6.7.3 Argentina Infertility Drugs Market Estimates and Forecasts, By End-user (2021-2032) (USD Billion)
10.6.8 Rest of Latin America
10.6.8.1 Rest of Latin America Infertility Drugs Market Estimates and Forecasts, By Drug Class (2021-2032) (USD Billion)
10.6.8.2 Rest of Latin America Infertility Drugs Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
10.6.8.3 Rest of Latin America Infertility Drugs Market Estimates and Forecasts, By End-user (2021-2032) (USD Billion)
11. Company Profiles
11.1 Teva Pharmaceutical Industries Ltd.
11.1.1 Company Overview
11.1.2 Financial
11.1.3 Product/ Services Offered
11.1.4 SWOT Analysis
11.2 Merck & Co., Inc.
11.2.1 Company Overview
11.2.2 Financial
11.2.3 Product/ Services Offered
11.2.4 SWOT Analysis
11.3 Ferring B.V.
11.3.1 Company Overview
11.3.2 Financial
11.3.3 Product/ Services Offered
11.3.4 SWOT Analysis
11.4 Abbott
11.4.1 Company Overview
11.4.2 Financial
11.4.3 Product/ Services Offered
11.4.4 SWOT Analysis
11.5 Novartis AG
11.5.1 Company Overview
11.5.2 Financial
11.5.3 Product/ Services Offered
11.5.4 SWOT Analysis
11.6 Bayer AG
11.6.1 Company Overview
11.6.2 Financial
11.6.3 Product/ Services Offered
11.6.4 SWOT Analysis
11.7 Livzon
11.7.1 Company Overview
11.7.2 Financial
11.7.3 Product/ Services Offered
11.7.4 SWOT Analysis
11.8 Mankind Pharma
11.8.1 Company Overview
11.8.2 Financial
11.8.3 Product/ Services Offered
11.8.4 SWOT Analysis
11.9 Sanofi
11.9.1 Company Overview
11.9.2 Financial
11.9.3 Product/ Services Offered
11.9.4 SWOT Analysis
11.10 Pfizer Inc.
11.10.1 Company Overview
11.10.2 Financial
11.10.3 Product/ Services Offered
11.10.4 SWOT Analysis
12. Use Cases and Best Practices
13. Conclusion
An accurate research report requires proper strategizing as well as implementation. There are multiple factors involved in the completion of good and accurate research report and selecting the best methodology to compete the research is the toughest part. Since the research reports we provide play a crucial role in any company’s decision-making process, therefore we at SNS Insider always believe that we should choose the best method which gives us results closer to reality. This allows us to reach at a stage wherein we can provide our clients best and accurate investment to output ratio.
Each report that we prepare takes a timeframe of 350-400 business hours for production. Starting from the selection of titles through a couple of in-depth brain storming session to the final QC process before uploading our titles on our website we dedicate around 350 working hours. The titles are selected based on their current market cap and the foreseen CAGR and growth.
The 5 steps process:
Step 1: Secondary Research:
Secondary Research or Desk Research is as the name suggests is a research process wherein, we collect data through the readily available information. In this process we use various paid and unpaid databases which our team has access to and gather data through the same. This includes examining of listed companies’ annual reports, Journals, SEC filling etc. Apart from this our team has access to various associations across the globe across different industries. Lastly, we have exchange relationships with various university as well as individual libraries.
Step 2: Primary Research
When we talk about primary research, it is a type of study in which the researchers collect relevant data samples directly, rather than relying on previously collected data. This type of research is focused on gaining content specific facts that can be sued to solve specific problems. Since the collected data is fresh and first hand therefore it makes the study more accurate and genuine.
We at SNS Insider have divided Primary Research into 2 parts.
Part 1 wherein we interview the KOLs of major players as well as the upcoming ones across various geographic regions. This allows us to have their view over the market scenario and acts as an important tool to come closer to the accurate market numbers. As many as 45 paid and unpaid primary interviews are taken from both the demand and supply side of the industry to make sure we land at an accurate judgement and analysis of the market.
This step involves the triangulation of data wherein our team analyses the interview transcripts, online survey responses and observation of on filed participants. The below mentioned chart should give a better understanding of the part 1 of the primary interview.
Part 2: In this part of primary research the data collected via secondary research and the part 1 of the primary research is validated with the interviews from individual consultants and subject matter experts.
Consultants are those set of people who have at least 12 years of experience and expertise within the industry whereas Subject Matter Experts are those with at least 15 years of experience behind their back within the same space. The data with the help of two main processes i.e., FGDs (Focused Group Discussions) and IDs (Individual Discussions). This gives us a 3rd party nonbiased primary view of the market scenario making it a more dependable one while collation of the data pointers.
Step 3: Data Bank Validation
Once all the information is collected via primary and secondary sources, we run that information for data validation. At our intelligence centre our research heads track a lot of information related to the market which includes the quarterly reports, the daily stock prices, and other relevant information. Our data bank server gets updated every fortnight and that is how the information which we collected using our primary and secondary information is revalidated in real time.
Step 4: QA/QC Process
After all the data collection and validation our team does a final level of quality check and quality assurance to get rid of any unwanted or undesired mistakes. This might include but not limited to getting rid of the any typos, duplication of numbers or missing of any important information. The people involved in this process include technical content writers, research heads and graphics people. Once this process is completed the title gets uploader on our platform for our clients to read it.
Step 5: Final QC/QA Process:
This is the last process and comes when the client has ordered the study. In this process a final QA/QC is done before the study is emailed to the client. Since we believe in giving our clients a good experience of our research studies, therefore, to make sure that we do not lack at our end in any way humanly possible we do a final round of quality check and then dispatch the study to the client.
By Drug Class
Gonadotropins
Dopamine Agonists
Aromatase Inhibitors
Selective Estrogen Receptor Modulators (SERMs)
Others
By Distribution Channel
Hospital Pharmacy
Online Pharmacy
Specialty & Retail Pharmacy
By End-user
Women
Men
Request for Segment Customization as per your Business Requirement: Segment Customization Request
North America
US
Canada
Mexico
Europe
Germany
France
UK
Italy
Spain
Poland
Turkey
Rest of Europe
Asia Pacific
China
India
Japan
South Korea
Singapore
Australia
Rest of Asia Pacific
Middle East & Africa
UAE
Saudi Arabia
Qatar
South Africa
Rest of Middle East & Africa
Latin America
Brazil
Argentina
Rest of Latin America
Request for Country Level Research Report: Country Level Customization Request
Available Customization
With the given market data, SNS Insider offers customization as per the company’s specific needs. The following customization options are available for the report:
Detailed Volume Analysis
Criss-Cross segment analysis (e.g. Product X Application)
Competitive Product Benchmarking
Geographic Analysis
Additional countries in any of the regions
Customized Data Representation
Detailed analysis and profiling of additional market players
